^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carboplatin

    i
    Other names: CBDCA, JM-8, JM8, NSC-241240, NSC-241240, NSC 241240, NSC-241-240
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    20h
    Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (clinicaltrials.gov)
    P3, N=1170, Active, not recruiting, Daiichi Sankyo | Trial completion date: May 2029 --> May 2031
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk)
    22h
    STAR-SCLC: Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • etoposide IV
    23h
    Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=29, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    carboplatin • paclitaxel
    1d
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
    P1/2, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • enzalutamide • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)
    1d
    Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, M.D. Anderson Cancer Center
    New trial
    |
    carboplatin • gemcitabine • docetaxel • melphalan
    1d
    Real Egyptian Single-Center Experience in Mantle Cell Lymphoma Diagnosis and Management. (PubMed, Indian J Hematol Blood Transfus)
    Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.
    Journal
    |
    CCND1 (Cyclin D1) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14)
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • prednisone • dexamethasone
    1d
    Carboplatin Elicits ROS Responses and Potentially Regulates Translation Program in Cancer Systems. (PubMed, J Biochem Mol Toxicol)
    The expression of single‑stranded DNA‑binding protein 1 (SSBP1), a mitochondrial translational regulator and a potential anti‑cancer target, was up‑regulated in carboplatin-treated cancer cells and in 22 tumor tissues, probably influencing the efficacy of chemotherapy. The potential crosstalk between mitochondrial translation and ROS response should be crucial for the clinical use of platinum drugs.
    Journal
    |
    RPA1 (Replication Protein A1)
    |
    carboplatin
    1d
    SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=410, Recruiting, Sinocelltech Ltd.
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    1d
    KRYSTAL-17: Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Mirati Therapeutics Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2026 --> Sep 2026
    Enrollment closed • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    1d
    SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=396, Not yet recruiting, Shanghai Chest Hospital
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • ALK fusion • ROS1 fusion
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Enshuxing (enlonstobart)
    1d
    DAREON-7: DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Apr 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • etoposide IV • obrixtamig (BI 764532)
    1d
    Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Fudan University
    New P2 trial
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)